Melinta Therapeutics appointed John Temperato as President and Chief Operating Officer. Prior to joining Melinta, John led the sales and managed markets division of Salix Pharmaceuticals. He played a critical role at Salix in the successful commercialization and growth of Xifaxan.

Prior to Salix, John held positions at Celltech Pharmaceuticals, where he was responsible for managed market strategy, Medeva Pharmaceuticals and Adams Laboratories.